Product Name
SCN1B, Blocking Peptide
Full Product Name
SCN1B Peptide
Product Gene Name
SCN1B blocking peptide
[Similar Products]
Product Synonym Gene Name
GEFSP1[Similar Products]
SCN1B peptide (MBS3227383) is used for blocking the activity of SCN1B antibody (MBS3202404)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q07699
Form/Format
Lyophilized powder
Preparation and Storage
Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20 degree C. Avoid repeat freeze-thaw cycles.
Other Notes
Small volumes of SCN1B blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
SCN1B blocking peptide
This is a synthetic peptide designed for use in combination with anti-SCN1B antibody made
Target Description: Voltage-gated sodium channels are essential for the generation and propagation of action potentials in striated muscle and neuronal tissues. Biochemically, they consist of a large alpha subunit and 1 or 2 smaller beta subunits, such as SCN1B. The alpha subunit alone can exhibit all the functional attributes of a voltage-gated Na+ channel, but requires a beta-1 subunit for normal inactivation kinetics.Voltage-gated sodium channels are essential for the generation and propagation of action potentials in striated muscle and neuronal tissues. Biochemically, they consist of a large alpha subunit and 1 or 2 smaller beta subunits, such as SCN1B. The alpha subunit alone can exhibit all the functional attributes of a voltage-gated Na+ channel, but requires a beta-1 subunit for normal inactivation kinetics.[supplied by OMIM].
Product Categories/Family for SCN1B blocking peptide
Peptide
Applications Tested/Suitable for SCN1B blocking peptide
Western Blot (WB)
NCBI/Uniprot data below describe general gene information for SCN1B. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001028
[Other Products]
NCBI GenBank Nucleotide #
NM_001037
[Other Products]
UniProt Primary Accession #
Q07699
[Other Products]
UniProt Related Accession #
Q07699[Other Products]
NCBI Official Full Name
sodium channel subunit beta-1 isoform a
NCBI Official Synonym Full Names
sodium voltage-gated channel beta subunit 1
NCBI Official Symbol
SCN1B??[Similar Products]
NCBI Official Synonym Symbols
ATFB13; BRGDA5; EIEE52; GEFSP1
??[Similar Products]
NCBI Protein Information
sodium channel subunit beta-1
UniProt Protein Name
Sodium channel subunit beta-1
Protein Family
Sodium channel
UniProt Gene Name
SCN1B??[Similar Products]
UniProt Entry Name
SCN1B_HUMAN
NCBI Summary for SCN1B
Voltage-gated sodium channels are heteromeric proteins that function in the generation and propagation of action potentials in muscle and neuronal cells. They are composed of one alpha and two beta subunits, where the alpha subunit provides channel activity and the beta-1 subunit modulates the kinetics of channel inactivation. This gene encodes a sodium channel beta-1 subunit. Mutations in this gene result in generalized epilepsy with febrile seizures plus, Brugada syndrome 5, and defects in cardiac conduction. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Oct 2009]
UniProt Comments for SCN1B
SCN1B: Crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the sodium channel. The subunit beta-1 can modulate multiple alpha subunit isoforms from brain, skeletal muscle, and heart. Its association with neurofascin may target the sodium channels to the nodes of Ranvier of developing axons and retain these channels at the nodes in mature myelinated axons. Defects in SCN1B are the cause of generalized epilepsy with febrile seizures plus type 1 (GEFS+1). Generalized epilepsy with febrile seizures-plus refers to a rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. GEFS+ is a disease combining febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity. Defects in SCN1B are the cause of Brugada syndrome type 5 (BRGDA5). A tachyarrhythmia characterized by right bundle branch block and ST segment elevation on an electrocardiogram (ECG). It can cause the ventricles to beat so fast that the blood is prevented from circulating efficiently in the body. When this situation occurs (called ventricular fibrillation), the individual will faint and may die in a few minutes if the heart is not reset. Belongs to the sodium channel auxiliary subunit SCN1B (TC 8.A.17) family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Channel, sodium
Chromosomal Location of Human Ortholog: 19q13.1
Cellular Component: voltage-gated sodium channel complex; T-tubule; extracellular region
Molecular Function: sodium channel inhibitor activity; sodium channel regulator activity; voltage-gated sodium channel activity
Biological Process: synaptic transmission; membrane depolarization; axon guidance; action potential propagation; corticospinal neuron axon guidance; cell adhesion; locomotion; response to pyrethroid; cardiac muscle contraction
Disease: Generalized Epilepsy With Febrile Seizures Plus, Type 1; Atrial Fibrillation, Familial, 13; Brugada Syndrome 5
Research Articles on SCN1B
1. The lack of genotype-phenotype concordance among families, combined with the high frequency of previously reported mutations in the Genome Aggregation Database browser, suggests that SCN1B is not a monogenic cause of BrS or SADS.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.